Table 2.

Improved or sustained GL-3 clearance from renal cells of patients who had Fabry disease and underwent long-term agalsidase β therapya

Renal Cell TypeNo. Evaluated at Month 6No. (%) with Score of 0No. Evaluated at Month 54bNo. (%) with Score of 0
Capillary endothelial cells4947 (96)88 (100)
Glomerular endothelial cells3535 (100)55 (100)
Mesangial cells3534 (97)55 (100)
Interstitial cells4843 (90)75 (71)
Noncapillary endothelial cells4440 (91)66 (100)
Noncapillary smooth muscle cells430 (0)60 (0)
  • a Patients with data at both pretreatment and month 6 or pretreatment and month 54 are summarized. GL-3, globotriaosylceramide.

  • b Of the extension study.